Pure Global
NCT06127199

Contraceptive Efficacy Study of Ovaprene

A Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene
Daré Bioscience, Inc.·ClinicalTrials.gov·device·Device trialNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Contraception
Drug/Device/Intervention
Ovaprene
Study type
Interventional
Intervention type
device
Sponsor & location
Primary sponsor
Daré Bioscience, Inc.
Location
Berkeley,Los Angeles,Sacramento,San Francisco,Aurora,Atlanta,Honolulu,Baltimore,Boston,Saint Louis,Newark,Bronx,New York,Cincinnati,Cleveland,Portland,Philadelphia,Pittsburgh,Salt Lake City,Norfolk, United States of America
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2023
End date
Sep 01, 2025
Enrollment
656 participants
Primary outcome

Determination of pregnancy rate

Summary

This will be a multi-center, single arm, open-label study of Ovaprene, a non-hormonal
 intravaginal ring, to investigate the contraceptive effectiveness, safety and acceptability
 of Ovaprene.

ICD-10 classifications
Contraceptive managementOral contraceptivesOther contraceptive managementGeneral counselling and advice on contraceptionPersonal history of contraception
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06127199
Type
Device Trial
About this record

Access comprehensive clinical trial information for NCT06127199 through Pure Global AI's free database. This phase not specified trial is sponsored by Daré Bioscience, Inc. and is currently Not yet recruiting. The study focuses on Contraception. Target enrollment is 656 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.